Tags

Type your tag names separated by a space and hit enter

Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
J Support Oncol 2007; 5(5):231-5JS

Abstract

The purpose of this study was to assess the relationship between oral mucositis (OM) and adverse clinical and economic outcomes of autologous hematopoietic stem-cell transplantation (HSCT) following high-dose melphalan (Alkeran) conditioning in patients with multiple myeloma. A retrospective study of 115 consecutive autologous HSCT recipients with multiple myeloma who received high-dose melphalan conditioning before transplantation was undertaken at a single academic center. OM severity was assessed twice weekly using a validated scale beginning 3-4 days following conditioning and continuing until hospital discharge or day 28, whichever occurred first. OM was graded, based on presence/extent of erythema/ulceration across eight oropharyngeal sites, as follows: 0 = no erythema or ulceration; I = erythema but no ulceration; II = ulceration, 1 site; III = ulceration, 2 sites; IV = ulceration, 3 sites; and V = ulceration, > or = 4 sites. Analyses examined the relationship between worst OM grade and selected clinical and economic outcomes, including days with fever, days of total parenteral nutrition (TPN),days of parenteral narcotic therapy, incidence of significant infection, and inpatient days and charges. The mean age of study subjects was 54 years; 19 patients (17%) received total-body irradiation, and 55 patients (48%) experienced OM grade > or = II (ie, ulceration). The worst OM grade was significantly (P < 0.05) associated with numbers of days of TPN and parenteral narcotic therapy, length of hospitalization, and total inpatient charges. Worst OM grade was not associated with the number of febrile days or the risk of significant infection. OM is associated with worse clinical and economic outcomes in multiple myeloma patients undergoing autologous HSCT following high-dose melphalan conditioning.

Authors+Show Affiliations

Policy Analysis Inc. (PAI), Brookline, Massachusetts 02445, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17564153

Citation

Vera-Llonch, Montserrat, et al. "Oral Mucositis and Outcomes of Autologous Hematopoietic Stem-cell Transplantation Following High-dose Melphalan Conditioning for Multiple Myeloma." The Journal of Supportive Oncology, vol. 5, no. 5, 2007, pp. 231-5.
Vera-Llonch M, Oster G, Ford CM, et al. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol. 2007;5(5):231-5.
Vera-Llonch, M., Oster, G., Ford, C. M., Lu, J., & Sonis, S. (2007). Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. The Journal of Supportive Oncology, 5(5), pp. 231-5.
Vera-Llonch M, et al. Oral Mucositis and Outcomes of Autologous Hematopoietic Stem-cell Transplantation Following High-dose Melphalan Conditioning for Multiple Myeloma. J Support Oncol. 2007;5(5):231-5. PubMed PMID: 17564153.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. AU - Vera-Llonch,Montserrat, AU - Oster,Gerry, AU - Ford,Colleen M, AU - Lu,John, AU - Sonis,Stephen, PY - 2007/6/15/pubmed PY - 2007/8/30/medline PY - 2007/6/15/entrez SP - 231 EP - 5 JF - The journal of supportive oncology JO - J Support Oncol VL - 5 IS - 5 N2 - The purpose of this study was to assess the relationship between oral mucositis (OM) and adverse clinical and economic outcomes of autologous hematopoietic stem-cell transplantation (HSCT) following high-dose melphalan (Alkeran) conditioning in patients with multiple myeloma. A retrospective study of 115 consecutive autologous HSCT recipients with multiple myeloma who received high-dose melphalan conditioning before transplantation was undertaken at a single academic center. OM severity was assessed twice weekly using a validated scale beginning 3-4 days following conditioning and continuing until hospital discharge or day 28, whichever occurred first. OM was graded, based on presence/extent of erythema/ulceration across eight oropharyngeal sites, as follows: 0 = no erythema or ulceration; I = erythema but no ulceration; II = ulceration, 1 site; III = ulceration, 2 sites; IV = ulceration, 3 sites; and V = ulceration, > or = 4 sites. Analyses examined the relationship between worst OM grade and selected clinical and economic outcomes, including days with fever, days of total parenteral nutrition (TPN),days of parenteral narcotic therapy, incidence of significant infection, and inpatient days and charges. The mean age of study subjects was 54 years; 19 patients (17%) received total-body irradiation, and 55 patients (48%) experienced OM grade > or = II (ie, ulceration). The worst OM grade was significantly (P < 0.05) associated with numbers of days of TPN and parenteral narcotic therapy, length of hospitalization, and total inpatient charges. Worst OM grade was not associated with the number of febrile days or the risk of significant infection. OM is associated with worse clinical and economic outcomes in multiple myeloma patients undergoing autologous HSCT following high-dose melphalan conditioning. SN - 1544-6794 UR - https://www.unboundmedicine.com/medline/citation/17564153/Oral_mucositis_and_outcomes_of_autologous_hematopoietic_stem_cell_transplantation_following_high_dose_melphalan_conditioning_for_multiple_myeloma_ L2 - http://www.diseaseinfosearch.org/result/4962 DB - PRIME DP - Unbound Medicine ER -